Percutaneous “edge-to-edge” leaflet repair in patient with primary mitral valve regurgitation

Giulio Rodinò, Giulia Masiero, Giuseppe Tarantini

Department of Cardiac, Thoracic, Vascular Science and Public Health, University of Padova, Padova 35128, Italy.

Correspondence to: Dr. Giuseppe Tarantini, Department of Cardiac, Thoracic and Vascular Science, University of Padova, Via Giustiniani 2, Padova 35128, Italy. E-mail: giuseppe.tarantini.1@gmail.com


Abstract
Mitral regurgitation (MR) is the most common left-sided heart valve disease in developed countries with a constantly rising number of patients requiring hospitalization or intervention. Organic MR is defined as a primary structural abnormality of the mitral valve (MV) apparatus which may be caused by a broad set of pathological processes, among which myxomatous degeneration of the leaflets causing MV prolapse is the most common. If left untreated, chronic severe MR leads to serious adverse outcomes, from heart failure to death, but medical therapy is unable to change the natural history of the disease. Surgical correction, by means of valve repair or replacement, is the gold standard for the treatment of symptomatic patients with severe primary MR. However, surgery is not feasible for a large percentage of patients because of old age, reduced left ventricular ejection fraction and the presence of severe comorbidities. Therefore, in recent years, several percutaneous therapeutic alternatives suitable for high or prohibitive surgical risk patients were developed. In this review we discuss the transcatheter treatment of primary MR, from available evidence to technical practice, with a focus on the percutaneous “edge-to-edge” leaflet repair performed with the MitraClip System and the PASCAL Repair System.

Keywords: Degenerative mitral valve disease, mitral regurgitation, mitral insufficiency, MitraClip, PASCAL

INTRODUCTION
Mitral regurgitation (MR) is the most common left-sided heart valve disease in developed countries with a prevalence that increases with age (from 0.5% among subjects 18-44 years old to 9.3% in the population...
over 75 years of age), which in the last decades has led to a sharp rise in the number of patients requiring hospitalization or intervention\(^1\). It is acknowledged that an organic (or primary) and a functional (or secondary) etiology of MR can be distinguished, and these two entities carry different prognosis and management\(^2\). The purpose of the current review is to outline the percutaneous treatment of primary MR, from available evidence to technical practice, with a focus on transcatheter “edge-to-edge” leaflet repair.

ETIOLOGY AND TREATMENT OF PRIMARY MR

Organic MR is defined as a primary structural abnormality of the mitral valve (MV) apparatus. Its etiology is largely dominated by myxomatous degeneration of the leaflets (which ranges from fibroelastic deficiency to Barlow’s disease), followed by rheumatic disease, infective endocarditis, connective tissue and ischemic disease, congenital malformations, and iatrogenic (radiation therapy or drugs) and traumatic lesions\(^3,4\). Fibroelastic deficiency usually presents with thin transparent leaflets with focal prolapse or flail due to chordal rupture, while Barlow’s disease hallmarks are multi-segment prolapse involving one or both leaflets in a valve with significant myxomatous changes, excess leaflet tissue and dilated annulus. Between these two phenotypes, a broad spectrum of degenerative disease is found in clinical practice\(^5\). Regardless of the anatomical background, MV prolapse is the most common cardiac valvular anomaly in developed countries affecting approximately 2% of the general population. It is associated with a variable degree of MR, with most patient having trivial or mild regurgitation; previous studies have found a 6% prevalence of a severe degree of the disease in the outpatient population with valve prolapse\(^6,7\). However, very little data are available in these patients regarding the progression of MR severity and the associated risk factors\(^8,9\).

Left untreated, chronic severe MR may lead to left ventricular (LV) remodeling because of volume overload, myocardial dysfunction, heart failure, left atrial dilatation, atrial fibrillation and pulmonary hypertension. Surgical correction, by means of valve repair or replacement, is the gold standard for the treatment of symptomatic patients with severe primary MR\(^2\). The optimal timing for intervention has to be according to symptom onset, worsening of LV function, significant LV dilatation, atrial fibrillation and pulmonary hypertension. Surgical correction, by means of valve repair or replacement, is the gold standard for the treatment of symptomatic patients with severe primary MR\(^2\). The optimal timing for intervention has to be according to symptom onset, worsening of LV function, significant LV dilatation, or development of atrial fibrillation or pulmonary hypertension. Despite the lack of randomized clinical trials comparing the results of valve replacement and repair, it is widely accepted that valve repair is the preferred treatment, when it is feasible and a durable repair is likely\(^2\). However, symptomatic patients are frequently denied surgical treatment mainly because of impaired LV ejection fraction, older age and comorbidities\(^3,10\). Therefore, in recent years, great effort was made to develop less invasive, percutaneous therapeutic alternatives suitable for high or prohibitive surgical risk patients. Possible catheter-based approaches for the treatment of MR include transapical or transseptal valve repair or replacement, placement of annular tightening devices, and insertion of artificial chordae. The “edge-to-edge” surgical repair technique, making a “double-orifice” MV, was the first to be adapted for the percutaneous approach with the MitraClip System (Abbott Vascular, Santa Clara, CA, USA), reaching over time more than 70,000 implants worldwide, since its first use in humans in 2003\(^11\). Later in 2019, the new PASCAL repair system (Edwards Lifesciences, Irvine, CA, USA) received CE mark for the percutaneous “edge-to-edge” repair treatment of MR, further expanding the therapeutic options available to the interventional cardiologist and the population eligible for treatment. As a matter of fact, current guidelines recommend a percutaneous edge-to-edge repair for the treatment of patients with symptomatic moderate-to-severe or severe primary MR who fulfill echocardiographic criteria of eligibility and are judged inoperable or at high surgical risk by the Heart Team evaluation (Class IIb, LOE C)\(^2\).

TECHNICAL ASPECTS OF TRANSCATHETER MV “EDGE-TO-EDGE” LEAFLET REPAIR

Proper patient selection with preoperative echocardiography using both 2D and 3D transesophageal echocardiography (TEE) is mandatory to confirm MR severity and define its mechanism while evaluating anatomic eligibility for an “edge-to-edge” transcatheter repair and, ultimately, achieve satisfactory results\(^1,12\). In the early years of MitraClip usage, eligibility was evaluated according to the preliminary
EVEREST trial inclusion and exclusion criteria\textsuperscript{[13]}; nowadays, thanks to the spread of the procedure, the growing experience of the operators and several technical improvements have allowed broadening the spectrum of suitable MV lesions, including some that were previously considered not feasible with good results, particularly in high-volume centers. Therefore, concerning eligibility for the procedure, MV anatomies may be divided into “optimal”, “challenging” and “advanced”, requiring increasing operator experience. Absolute contraindications to the percutaneous “edge-to-edge” technique are still represented by very short posterior leaflet, high degree of calcification in leaflet grasping area, MV area < $3\text{ cm}^2$ and rheumatic MR\textsuperscript{[15,14]} [Table 1]. An interesting topic is the management of MR of mixed or undetermined etiologies, but data in this regard are still scant. To date, only few registries report an incidence ranging from 3% to 10% in real-world practice; however, their results have focused only on degenerative and functional etiology for outcome data analysis. As a matter of fact, standardized criteria to define a “mixed etiology” are lacking, making it difficult to achieve a shared definition among different studies, and in most cases a predominant etiology between organic and functional may be individualized with a careful multiparametric evaluation, allowing classification of the MR into one of the two dichotomous categories.

The MitraClip System consists of a 24 Fr guide catheter and a clip delivery system, which includes one detachable clip [Figure 1]. The system is steerable using two knobs, which allow medial-lateral and anterior-posterior deflection; moreover, the clip delivery system includes a control mechanism by which the clip arms are opened and closed. The procedure is performed in the catheterization laboratory, under general anesthesia and with fluoroscopic and TEE guidance. A transseptal approach is used, and the puncture has to be performed in the posterosuperior part of the fossa ovalis, 4.5 cm ± 0.5 cm from the MV plane, to guarantee optimal maneuverability of the clip delivery system in the left atrium. Therefore, the clip is aligned on the main regurgitation jet, perpendicularly to the MV line of coaptation. Subsequently, arms are opened with a 180° angle, grippers are raised, the system is advanced into the LV and then retracted until reaching a position where firm grasping of both leaflets can be expected. Finally, the leaflets are grasped with grippers and clip arm closure and the presence of adequate “tissue-bridge” inside the device as well as the amount of residual MR and mitral gradient need to be evaluated. If the result is acceptable, the device is deployed by maneuvering the clip delivery system. If needed, particularly in complex anatomies (i.e., cleft, commissural fail, Barlow’s disease, \textit{etc}), more than one clip may be positioned. In this case, residual MR and transvalvular gradients must be re-assessed for each additional clip. Main possible complications of the procedure include peripheral vascular injury, injury of surrounding cardiac structures during transseptal puncture, potentially causing cardiac tamponade requiring pericardiocentesis, clip detachment and embolization or clip entanglement in the chordae tendineae with possible damage\textsuperscript{[15]}.  

Compared to the first-generation device that was launched in 2008, the current generation includes two different versions: the MitraClip NT\textsubscript{R} and the MitraClip XT\textsubscript{R}. The former is an evolution of the previous

<table>
<thead>
<tr>
<th>Optimal valve morphology</th>
<th>Possible valve morphology</th>
<th>Tough/unsuitable valve morphology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginner operator</td>
<td>Average operator</td>
<td>Expert operator</td>
</tr>
<tr>
<td>Central pathology (A2/P2 scallops)</td>
<td>Commissural pathology (A1/P1 or A3/P3 scallops)</td>
<td>Barlow’s syndrome, flail in multiple scallops</td>
</tr>
<tr>
<td>No calcification</td>
<td>Mild calcification outside grasping zone, annulus calcification, previous annuloplasty</td>
<td>Significant calcification of grasping zone</td>
</tr>
<tr>
<td>MVA &gt; 4 cm\textsuperscript{q}</td>
<td>MVA &gt; 3 cm\textsuperscript{q}, preserved mobility</td>
<td>-</td>
</tr>
<tr>
<td>Posterior leaflet length ≥ 10 mm</td>
<td>Posterior leaflet length 7-10 mm</td>
<td>Posterior leaflet length &lt; 7 mm</td>
</tr>
<tr>
<td>Tenting height &lt; 11 mm</td>
<td>Tenting height &gt; 11 mm</td>
<td>-</td>
</tr>
<tr>
<td>Normal leaflet thickness and mobility</td>
<td>Restricted leaflet motion during systole</td>
<td>Restricted leaflet motion during systole and diastole, rheumatic disease</td>
</tr>
<tr>
<td>Flail gap &lt; 10 mm and width &lt; 15 mm</td>
<td>Flail width &gt; 15 mm with dilated annulus (multiple clip implantation)</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 1. Classification of MV morphology based on anatomical criteria for MitraClip implantation procedure

MV: mitral valve; MVA: mitral valve area
A second generation device (the MitraClip NT) with an enhanced delivery system, whereas the latter is a completely new version, with larger and longer arms and grippers that should allow a deeper and more stable grasping, particularly in case of large coaptation gaps or redundant MV tissue, frequently encountered in the degenerative settings.

The PASCAL Repair System consists of a 10-mm central spacer, intended to fill the regurgitation area, and two broad paddles intended to maximize leaflet coaptation and reduce stress on the grasping area (when closed, the paddles also dynamically flex on every heartbeat, as the valve opens and closes). The implant has clasps that allow for independent leaflet capture and offer the possibility to fine-tune leaflet positioning. The 22 Fr delivery system includes three catheters: a guide sheath, a steerable catheter, and an implant catheter used to deliver the implant. The three independent catheter movements in all planes allow access to different locations across the coaptation line and a very simple control of position and orientation of the device [Figure 2]. All these features were designed to overcome some of the technical limitations of the MitraClip system in complex anatomies, such as short posterior leaflet, large flail gaps, severe tethering, and severe annular dilatation. Specifically, in a degenerative mitral regurgitation (DMR) setting: the independent catheters should simplify the navigation in the left atrium and the orientation of the device; the larger size of the implant should achieve effective MR reduction; and the wide paddles and optional independent leaflet grasping should ensure reaching a straight leaflet insertion in case of challenging anatomies, with no determinant impact on post-procedural MV gradient. However, further studies are needed to assess the safety and effectiveness of this novel device in this complex anatomical setting.

EVIDENCE ON PERCUTANEOUS “EDGE-TO-EDGE” LEAFLET TREATMENT IN PRIMARY MR

Current evidence about the efficacy and safety of the MitraClip in the setting of organic MR is mostly based on the initial EVEREST cohort, the EVEREST II randomized trial and single or multicenter worldwide registries [Table 2]. The EVEREST pilot study enrolled 107 patients, of which 79% presented with degenerative MR. Acute procedural success occurred in 74% of recruited patient and 9% experienced major adverse events (MAE) at 30-day follow-up. The primary efficacy endpoint, a composite of freedom from death, MV surgery and residual MR > 2+, occurred in 66% of the population at 1 year and remained stable at 2 and 3-year of follow up, while 30% of patients had MV surgery up to 3 years after the clip procedure. In the randomized EVEREST II trial, the MitraClip system was compared to conventional MV surgery; 279 patients were enrolled and almost one-third of the population had complex degenerative MR with either Barlow’s disease or anterior leaflet prolapse. The MitraClip procedure was associated with lower MAE incidence at 30 days follow-up (48% vs. 15%, P < 0.001). This primary safety endpoint was defined as the composite of death, myocardial infarction, reoperation for failed mitral valve surgery, nonelective
cardiovascular surgery for adverse events, stroke, renal failure, deep wound infection, mechanical ventilation for more than 48 h, gastrointestinal complication requiring surgery, new-onset permanent atrial fibrillation, septicemia, and transfusion of 2 units or more of blood; to note, the former was the major driver of superiority for the MitraClip procedure. When considering any MAE excluding transfusion, no significant differences were observed between surgical and percutaneous treatment. At 12 months follow-up, the primary efficacy endpoint was greater in the surgical group compared to the percutaneous group (respectively 73% vs 55%, P = 0.007) but with similar improvements in clinical outcomes such as LV size, New York Heart Association (NYHA) functional class and quality of life measures. At a longer follow-up, patients requiring surgery for residual MR or MV dysfunction during the first year after treatment were more commonly those initially treated with percutaneous repair, but comparatively low rates of surgery were observed in both groups between 1- and 5-year follow-up. More recently, Bizzatti et al. showed lower acute postoperative complications and improved 1-year survival after MitraClip treatment compared to surgery in elderly patients (age > 75) affected by primary MR and STS-PROM < 8%. However, the percutaneous procedure was once again associated with greater MR recurrence and reduced survival

<table>
<thead>
<tr>
<th>Registry</th>
<th>No. of pts.</th>
<th>Age</th>
<th>Primary MR</th>
<th>Procedural success</th>
<th>30-day mortality</th>
<th>1-year mortality</th>
<th>1-year MR grade ≤ 2+</th>
<th>1-year NYHA class ≤ II</th>
</tr>
</thead>
<tbody>
<tr>
<td>REALISM</td>
<td>351</td>
<td>76 ± 11</td>
<td>30%</td>
<td>86%</td>
<td>5%</td>
<td>23%</td>
<td>83.6%</td>
<td>82.9%</td>
</tr>
<tr>
<td>ACCESS-EU</td>
<td>567</td>
<td>74 ± 10</td>
<td>23%</td>
<td>91%</td>
<td>3%</td>
<td>17%</td>
<td>78.9%</td>
<td>71.4%</td>
</tr>
<tr>
<td>SENTINEL</td>
<td>628</td>
<td>74 ± 10</td>
<td>23%</td>
<td>95%</td>
<td>-</td>
<td>15%</td>
<td>94%</td>
<td>74.2%</td>
</tr>
<tr>
<td>TRAMI</td>
<td>828</td>
<td>76 (71-81)</td>
<td>29%</td>
<td>97%</td>
<td>5%</td>
<td>20%</td>
<td>-</td>
<td>63.3%</td>
</tr>
<tr>
<td>GRASP-IT</td>
<td>304</td>
<td>72 ± 10</td>
<td>21%</td>
<td>92%</td>
<td>3%</td>
<td>13%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STS/ACC TVT</td>
<td>2952</td>
<td>82 (74-86)</td>
<td>86%</td>
<td>92%</td>
<td>5%</td>
<td>26%</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MITRA-SWISS</td>
<td>100</td>
<td>72 ± 12</td>
<td>38%</td>
<td>85%</td>
<td>-</td>
<td>15%</td>
<td>78%</td>
<td>80%</td>
</tr>
</tbody>
</table>

Table 2. Real-world registries on safety and efficacy results of the MitraClip procedure

Figure 2. Upper panel shows the PASCAL Delivery System handle, comprising three different parts, one for each catheter. Independent movement of the three catheters is actuated by the use of control knobs. Lower panel shows the PASCAL implant in the closed, opened and elongated configurations (from left to right, respectively)

pts: patients; MR: mitral regurgitation; NYHA: New York Heart Association
beyond 1 year of follow-up. As a matter of fact, current clinical guidelines still recommend surgical valve repair as the gold standard for the treatment of primary MR, restricting the percutaneous “edge-to-edge” option to patients judged inoperable or at high surgical risk. In this population, improvements in quality of life, NYHA functional class, LV reverse remodeling and reduction in heart failure hospitalizations are consistently observed after treatment with MitraClip. Data on the new MitraClip XT are still limited to initial experiences in selected patients with DMR and complex MV anatomies, such as Barlow’s disease. A large observational prospective study, the MitraClip EXPAND Study (NCT03502811) is designed to enroll up to 1000 patients to confirm the safety and performance of the NT and XT System, identifying trends in patient selection for MitraClip therapy in a real-world use.

Current data about the PASCAL Repair System are limited to the first-in-man study, which enrolled 23 patients, and the CLASP study, a multicenter prospective single-arm study in 62 patients with primary and secondary moderate-to-severe or severe MR (36% of degenerative etiology). In the latter, successful implantation was achieved in 95% of patients. At 30 days, encouraging results were shown, with a MAE rate of 6.5%, with an all-cause mortality rate of 1.6% and no occurrence of stroke; procedural residual MR grade 2+ or less was achieved in 98% patients, and 85% were in NYHA functional class I or II. The mean 6-min walk distance increased by 36 m from baseline and both the Kansas City Cardiomyopathy Questionnaire and EQ-5D Health Questionnaire scores improved significantly. Further results collecting 6-month and 1-year follow-up have been recently presented showing sustained results compared to the previous one. The forthcoming Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial (CLASP IID/IIF; NCT03706833) is the first randomized controlled trial that is going to specifically investigate the safety and effectiveness of the Pascal system compared to the MitraClip system in patients with degenerative MR at high or prohibitive risk for MV surgery by the Heart Team.

CASE EXAMPLE: PRIMARY MR TREATED WITH THE MITRACLIP SYSTEM

We report here the case of a 75-year-old man affected by symptomatic severe degenerative MR and a history of hypertension, paroxysmal atrial fibrillation and ischemic cardiopathy initially treated with triple coronary artery bypass graft and later with percutaneous coronary stenting on left main and circumflex artery because of venous graft occlusion. He also underwent mechanical aortic valve prothesis implantation because of severe aortic insufficiency and several comorbidities, including beta-thalassemia minor with moderate-to-severe anemia often requiring blood transfusions, chronic obstructive pulmonary disease, kyphoscoliosis, left kidney atrophy with chronic renal insufficiency and previous thoracic radiotherapy and splenectomy for the treatment of a Hodgkin’s lymphoma. A 2D and 3D transthoracic echocardiogram showed a normal-sized left ventricle with preserved EF and unchanged regional wall motion abnormalities, a well-functioning mechanical aortic prothesis and a severe MR due to P2 leaflet prolapse extended to P3 and a P1-P2 cleft. Of note, calcification of the anterior leaflet was present outside the grasping area reducing mobility and producing a mean gradient of 3 mmHg. Left atrium was severely dilated, and a moderate tricuspid regurgitation was also detected, with a mean arterial pressure of 37 mmHg. These findings were confirmed with 2D and 3D TEE, which allowed us to positively assess anatomic suitability of MitraClip implant. After multidisciplinary Heart Team clinical evaluation, the patient became a suitable candidate for percutaneous “edge-to-edge” repair, with an intended treatment strategy of implantation of two convergent clips. The procedure was carried out through a right femoral venous access and under fluoroscopic and both 2D and 3D TEE guidance. The transseptal puncture was done in a posterosuperior position of the fossa ovalis with a measured height of 4.3 cm over the atrioventricular plane. A guidewire was then positioned in the left superior pulmonary vein and the MitraClip delivery system was advanced into the left atrium. The first clip was aligned on the main regurgitation jet in A2-P2 position with a slight counterclockwise orientation, arms were opened with a 180° angle, grippers were raised, and the clip was advanced into the left ventricle. The system was then retracted to reach a stable grasping of both leaflets and clip arms were closed. Therefore, after a careful TEE final assessment, the first clip was deployed. The same procedural steps were repeated for the placement of a
Figure 3. Preoperative evaluation with 2D (A, C, D) and 3D (B) TEE. White arrows indicate P2 prolapse; red arrow indicates P1-P2 cleft. Color TEE (C, D) shows 2 regurgitation jets (green arrows) with the main one localized at the level of P2 prolapse, producing severe mitral regurgitation.

Figure 4. Transseptal puncture under fluoroscopic (A) and TEE (B) guidance. A puncture 4 to 4.5 cm above the MV plane in a posterosuperior position allows good maneuverability of the delivery system. After the transseptal puncture, a guidewire is introduced in the left atrium and then in the left superior pulmonary vein (C).

second clip lateral to the first one, with a slight clockwise orientation, in P1-A2 position [Figure 6]. At the end of the procedure, mild residual MR was detected with a mean gradient less than 5 mmHg [Figure 7].
Figure 5. Implantation of a first MitraClip. The device is aligned with the main regurgitation jet at P2 prolapse, perpendicularly to the coaptation plane and slightly oriented counterclockwise (A); under TEE (B) and fluoroscopic (C) guidance, clip arms are opened, the device is advanced in the left ventricle and then retracted to grasp both leaflets.

Figure 6. Implantation of a second MitraClip. The second device is placed in P1-A2 position with a slight clockwise orientation compared to the first Clip (convergent clip technique) under 3D TEE (A), X-plan view on TEE (B) and fluoroscopic (C) guidance.

Figure 7. Final result. The 3D TEE shows the new “double orifice” mitral valve (A, B) with mild residual mitral regurgitation (C, D); continuous doppler (E) shows a final transvalvular gradient less than 5 mmHg.
The patient was discharged after 3 days without peri-procedural complications. After 30 days, a follow-up transthoracic echocardiogram showed mild MR and stable transvalvular gradients. One year later the patient confirmed a clinical status improvement (NYHA functional class I-II) with no further hospital admissions for heart failure.

DECLARATIONS

Authors’ contributions

Participated to the conception and the drafting of the manuscript, its critical revision for important intellectual content and the final approval of the submitted text; agreed for all aspects of the work ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: Rodinò G, Masiero G, Tarantini G

Availability of data and materials

Not applicable.

Financial support and sponsorship

None.

Conflicts of interest

Tarantini G reports honoraria for lectures from Abbott Vascular and Edwards Lifesciences; Rodinò G and Masiero G declared that there are no conflicts of interest.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Copyright

© The Author(s) 2020.

REFERENCES
